Rigel Pharmaceuticals, Incorporated

Chemocentryx, Inc.

Arlo Technologies, Inc.

Chiron Corporation

Other

University of California

Bristol-myers Squibb Compnay

Array Biopharma Inc.

Novartis Ag

Bristol Meyers Squibb Company

Neutrino8, Inc.

Rigl Pharmaceutical, Inc.

Rogel Pharmaceuticals, Inc.

Rajinder Paul Singh

Hui Li

Somasekhar Bhamidipati

Ankush Argade

Jeffrey Clough

Sacha Holland

Donald G Payan

Vanessa Taylor

Holger Keim

Catherine Sylvain

Jiaxin Yu

Kin Tso

Thilo J Heckrodt

Dane A Goff

Esteban Masuda

Pingyu Ding

David Carroll

Yan Chen

Sambaiah Thota

Penglie Zhang

Ihab S Darwish

Jing Zhang

Alexander B Rossi

Susan Molineaux

Darren J McMurtrie

Rose Yen

Matthew Duncton

Ju Yang

Hui Hong

Rao Kolluri

Venkat Reddy Mali

Viengkham Malathong

Robin Cooper

Sreenivas Punna

Thomas Weitao Sun

Joane Litvak

Xiang Xu

Arvinder Sran

Marina Gelman

Christopher W Lange

Todd M Kinsella

Rebecca M Lui

Pingchen Fan

Simon Shaw

Ryan Kelley

Salvador Alvarez

Yibin Zeng

John Yudhistir Ramphal

Hiroko Tanaka

Valentino J Stella

Jeffrey P McMahon

Chao Yu

Henry Lu

Manmohan Reddy Leleti

Thomas J Schall

Dean R Dragoli

Carlos A Valdez

Brian Wong

Xi Chen

Yasumichi Hitoshi

Jack Maung

Andy Atuegbu

Vadim Markovtsov

Haoran Zhao

Howard S Roth

Manoj C Desai

Xiaodong Lin

Verena D Huebner

Liya Chen

Liang Wang

Beata Krywult

Ian James

Zhenhua Miao

James J Campbell

Dennis Aldover

John McLaughlin

Sarkiz D Issakani

Jay Patrick Powers

Jaroslaw Kalisiak

Junfa Fan

Upender Velaparthi

Jayakumar Sankara Warrier

Taisei Kinoshita

Hasibur Rahaman

Xiaohong Shen

John Thomas

Peiying Liu

Yu Wang

Ping Li

John Joseph Partridge

Antoni Krasinski

Robert Michael Borzilleri

Israel Charo

Chetan Padmakar Darne

Gary Charles Look

Ihab Abu-Hakima

Paul A Renhowe

John M Nuss

Guy J Laidig

An electronic monitoring system for secure image code generation and a method of activating devices in the electronic monitoring system via the secure image codes are provided. The electronic monitoring system includes a base station in communication with a monitoring device. The monitoring device includes a camera to obtain images of a monitored area. A controller for the electronic monitoring system receives a request for a desired interaction with the electronic monitoring system from a first device and generates multiple image codes corresponding to the desired interaction. The controller transmits the image codes to a mobile device and then receives each of the image codes from the camera when the image codes are displayed on the mobile device while the mobile device is positioned in front of the camera. The controller activates the desired interaction with the electronic monitoring system responsive to receiving the image codes from the camera.

Dynamic image based contactless instructions for an electronic monitoring system

A method and system are provided for securely onboarding a Bluetooth Low Energy peripheral device or other peripheral device operating over a personal area network (PAN) onto a cloud-based network system. The method includes providing a private-public key pair, wherein the private key is stored on the peripheral device and the public key is stored on a database within the cloud-based network system. Upon user activation, the peripheral device begins advertising, using a PAN communications protocol, a first hash value generated with the private key, which is received at the cloud-based processor and verified with the corresponding public key. In response to verifying the first hash value, the cloud-based processor transmits a public key encrypted random code, which is received at the peripheral device and decrypted with the private key. In response, the peripheral device then transmits a second hash value generated with the private key, which is also received at the cloud-based processor and is then verified with the public key.

Method and system for the secure onboarding of low energy peripheral devices

Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, X, Z, m, p, and Rare as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-β superfamily, and can be used to treat disease by blocking such activity.

TGF-β inhibitors

A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

Method of treating focal segmental glomerulosclerosis

A method of updating of firmware to a client device such as a BLE button is provided. The method includes the steps of providing a first user device and detecting the client device with the first user device. It is determined if the client device is in an update mode in response to instructions from a second user device. The firmware is uploaded from the first user device to the client device in response to the client device being in the update mode.

Method to securely update over-the-air firmware

An electronic monitoring system has one or more imaging devices that can detect a triggering event based on motion and/or sound and that concurrently provide a push notification to a user device with a custom audio alert indicative of the one or more triggering events for quickly identifying the triggering without requiring the remote device to execute a dedicated application program. The custom audio alert portion of the push notification may provide various details of the triggering event, categorized as either a genus level triggering event and/or a species level triggering event, i.e., a subset of the genus level triggering event. The push notification can operate as a custom audio alert and a pop-up message which can be pushed to the device and broadcast or displayed via an operating system of the device.

Electronic monitoring system using push notifications with custom audio alerts

Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.

2-oxindole compounds

Disclosed are novel benzazole compounds and compositions comprising the compounds. The compounds are useful as kinase inhibitors including interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Benzazole compounds and methods for making and using the compounds

The present disclosure is drawn to the combination therapy of a C-C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors

Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

IRAK inhibitors and method for making and using

The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula I or Formula III:

Methods of treating solid tumors with CCR2 antagonists

Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Amide compounds and method for making and using

An electronic monitoring system has one or more imaging devices that can detect at least one triggering event comprising sound and motion and a controller that executes a program to categorize the triggering event as being located in a user-defined activity zone within the field of view and/or as being a taxonomic-based triggering event. Upon categorizing the triggering event, the system generates an output comprising a video component and an audio component. At least a portion of the audio component is modified if the triggering event is a categorized triggering event. Modification of the audio may include muting all or a portion of the audio component of the output.

Electronic monitoring system having modified audio output

Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.

Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies

Compounds represented by Formula (I) or (II): are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, Y, Y′, and the subscripts m and n are as defined herein.

Indanes as PD-L1 inhibitors

Growing community of inventors

Davis, CA, United States of America

Rajinder Paul Singh